/
ANNX
$5.57+$0.09 (+1.64%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$897.9M
164M shares
52-week range
$1.85 – $7.18
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.37%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-16.94
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $488.0K | $0 | $0 | $0 | $0 | $0 | $3.5M | $3.7M |
| Gross profit | −$488.0K | $0 | $0 | $0 | $0 | $0 | −$3.5M | −$3.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $15.5M | $24.5M | $49.3M | $100.1M | $112.5M | $113.8M | $119.4M | $184.7M |
| Operating income | −$19.1M | −$32.5M | −$63.5M | −$130.7M | −$145.6M | −$143.7M | −$154.1M | −$216.4M |
| EBITDA | −$18.7M | −$32.0M | −$62.8M | −$128.2M | −$139.8M | −$132.1M | −$134.7M | −$204.0M |
| Net income | −$18.3M | −$37.2M | −$63.4M | −$130.3M | −$141.9M | −$134.2M | −$138.2M | −$206.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.60 | -0.97 | -3.70 | -3.34 | -2.60 | -1.77 | -1.01 | -1.34 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.95 | $-1.04–$-0.89 | 7 |
| 2027 | $45M | $-0.80 | $-1.11–$-0.40 | 6 |
| 2028 | $300M | $0.08 | $-0.13–$0.57 | 6 |
| 2029 | $618M | $1.18 | $-0.08–$3.43 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.79
Price
$5.57
Implied downside
-86%
Peer comparison
Annexon, Inc. Common Stock
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
www.annexonbio.com- Employees
- 93
- IPO / List date
- Jul 24, 2020
- HQ
- BRISBANE, CA
Held by traders on TradeandTell
No one on the platform currently holds ANNX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 544,300 | $3.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANNX yet.
